Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials
Robert Bissonnette,Richard B Warren,Andreas Pinter,Tove Agner,Melinda Gooderham,Marie L A Schuttelaar,Marie-Noëlle Crépy,Luca Stingeni,Esther Serra-Baldrich,Keith Baranowski,Sofie Korn,Merle Kurvits,Ursula Plohberger,Natacha Strange Vest,Sibylle Schliemann,trial investigators,Charles Lynde,Lyn Guenther,Maxwell Sauder,Jaggi Rao,Isaiah Day,Alim Devani,Andrei Metelitsa,Parbeer Grewal,Sonja Molin,Mireille Ruer-Mulard,Françoise Giordano-Labadie,Hervé Maillard,Ziad Reguiai,Claire Bernier,Camille Leleu,Julien Seneschal,Delphine Staumont-Sallé,Thomas Hubiche,Caroline Jacobzone,Abdallah Khemis,Margitta Worm,Andrea Bauer,Sabine Sell,Swarna Ekanayake-Bohlig,Sylvia Pauser,Timo Buhl,Andreas Schwinn,Bernadette Eberlein,Sven Quist,Boris Bauer,Ketty Peris,Maria Teresa Rossi,Maria Fargnoli,Luigi Naldi,Silvia Ferrucci,Irena Walecka-Herniczek,Dorota Krasowska,Aleksandra Lesiak,Aleksandra Okuniewska,Grażyna Pulka,Malgorzata Dyczek,Bartlomiej Kwiek,Rafal Czajkowski,Hanna Myśliwiec,Padma Mohandas,Sandeep Cliff,Richard Warren,Pippa Cousen,Graham Johnston,Richard Woolf,Kim Papp,David Adam,Darryl Toth,Chih-Ho Hong,Irina Turchin,Firouzeh Niakosari,Elena Poulos,Jason Rivers,Jason Ohayon,Milan Tjioe,Thomas Rustemeyer,Marjolein S de Bruin-Weller,Judith Molhoek,Bert Oosting,Markus Kaspari,Nina Magnolo,Michael Sebastian,Diamant Thaci,Peter Radny,Nicolas Leitz,Athanasios Tsianakas,Amir Yazdi,Maria Kamstrup,Mette Sommerlund,Claus Zachariae,Witold Owczarek,Monika Dudra-Jastrzebska,Adam Reich,Elzbieta Kowalska-Oledzka,Jacek Szepietowski,Maria Poznanska,Jolanta Weglowska,Olivier Aerts,Pierre-Paul Roquet-Gravy,Sven Lanssens,Francisca Castelijns,Christelle Scheers,Erwin Suys,Bernard Kint,José Manuel Carrascosa,Pablo de la Cueva Dobao,Rosa Izu,Juan Francisco Silvestre,Pablo Coto-Segura,Almudena Fernández-Orland
DOI: https://doi.org/10.1016/S0140-6736(24)01027-4
2024-08-03
Abstract:Background: Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema. Methods: Both trials were randomised, double-blinded, and vehicle-controlled, with DELTA 1 being conducted at 53 trial centres in Canada, France, Germany, Italy, Poland, and the UK and DELTA 2 at 50 trial centres in Belgium, Canada, Denmark, Germany, the Netherlands, Poland, and Spain. Adults (aged ≥18 years) with moderate to severe chronic hand eczema were randomly assigned 2:1 to twice-daily delgocitinib cream 20 mg/g or cream vehicle for 16 weeks. The primary endpoint was Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) treatment success at week 16, defined as IGA-CHE score of 0 (clear) or 1 (almost clear, defined as only barely perceptible erythema). Efficacy and safety were assessed in all patients who were exposed to trial treatment. These trials are registered with ClinicalTrials.gov, NCT04871711 and NCT04872101. Findings: Between May 10, 2021, and Oct 31, 2022, 487 patients (181 male and 306 female) were enrolled in DELTA 1; between May 25, 2021, and Jan 6, 2023, 473 patients (161 male and 312 female) were enrolled in DELTA 2. 325 patients in DELTA 1 and 314 in DELTA 2 were assigned to delgocitinib cream; 162 patients in DELTA 1 and 159 in DELTA 2 were assigned to cream vehicle. At week 16, a greater proportion of delgocitinib-treated patients versus cream vehicle patients had IGA-CHE treatment success (64 [20%] of 325 vs 16 [10%] of 162 in DELTA 1 and 91 [29%] of 313 vs 11 [7%] of 159 in DELTA 2; both trials p≤0·0055). The proportion of patients who reported adverse events was similar with delgocitinib (147 [45%] of 325 in DELTA 1 and 143 [46%] of 313 in DELTA 2) and the cream vehicle (82 [51%] of 162 in DELTA 1 and 71 [45%] of 159 in DELTA 2). Most frequent adverse events occurring in at least 2% of patients were similar in both treatment groups and included COVID-19 and nasopharyngitis. Interpretation: Overall, delgocitinib cream showed superior efficacy versus cream vehicle and was well tolerated over 16 weeks. These results support the clinical benefit of delgocitinib cream as a potential treatment option for patients with moderate to severe chronic hand eczema, who are unable to adequately control their disease with basic skin care practices and topical corticosteroids. Funding: LEO Pharma.